PDF(1450 KB)
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in non-small cell lung cancer with different PD-L1 expression levels based on partitioned survival model
XU He, MA Ai-xia
Chinese Journal of Hospital Pharmacy ›› 2020, Vol. 40 ›› Issue (23) : 2468-2473.
PDF(1450 KB)
PDF(1450 KB)
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in non-small cell lung cancer with different PD-L1 expression levels based on partitioned survival model
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
